New cell therapy brings new hope for relapsed patients treated by CAR-T treatment

• Facebook
• Twitter
• Reddit
• Tumblr
• LinkedIn
• Pinterest
• RSS Feed
• Link

New cell therapy brings new hope for relapsed patients treated by CAR-T treatment

• Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
• Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
• FDA has mandated a top-level black box warning for all marketed CAR-T therapies
• Can people with high blood pressure eat peanuts?
• What is the difference between dopamine and dobutamine?
• How long can the patient live after heart stent surgery?

100% objective response rate : New cell therapy brings new hope for relapsed patients treated by CAR-T treatment.

On June 09, Precision BioSciences announced the latest clinical trial results of its allogeneic investigational CAR-T therapy PBCAR0191 constructed using ARCUS gene editing technology.

In the treatment of diffuse large B-cell lymphoma (DLBCL) patients who had relapsed after autologous CAR-T therapy, PBCAR0191 achieved a 100% objective response rate, a 73% complete response rate, and 50% of patients had a response duration of more than 6 months.

At present, 6 autologous CAR-T cell therapies have been approved by the US FDA to treat a variety of different blood cancers.

Although some patients achieve sustained remission after receiving treatment, there are also many patients whose disease relapses even after receiving autologous CAR-T therapy.

The prognosis for these patients is particularly poor, with progression-free survival of only one or two months.

Precision BioSciences pointed out that as autologous CAR-T therapy is used in more patients, the number of patients who relapse after receiving autologous CAR-T therapy may increase by 4-5 times by 2025.

PBCAR0191 is an off-the-shelf allogeneic CAR-T therapy produced by Precision BioSciences using a homing endonuclease technology called ARCUS for gene editing.

This endonuclease is a meganuclease that can perform highly specific cleavage in cellular DNA. It completes the cleavage by recognizing the target sequence containing 22 bases.

Due to the long target sequence, there is little chance of off-target editing, and after editing, it will be automatically inactivated, thereby further reducing off-target editing.risk.

PBCAR0191 is a CAR-T therapy targeting CD19.

Image source: Precision BioSciences official website

The latest clinical trial results showed that PBCAR0191 achieved an objective response rate of 100% in 11 patients whose disease relapsed after receiving autologous CAR-T therapy.

Eight of these patients achieved complete remission when assessed 28 days after treatment.

Of the 6 patients whose duration of response was evaluable, 3 patients had responses lasting longer than 6 months.

The company noted that this remission data is better than current CAR-T therapy for patients who have relapsed after receiving standard therapy.

▲ Clinical trial results of PBCAR0191 (Image source: PBCAR0191)

“New clinical data shared today show that PBCAR0191 is able to produce high clinical response rates in patients who have relapsed after CAR-T therapy. They have received a median of 5 prior therapies. We believe these data support the use of PBCAR0191 for the treatment of this A regulatory pathway for a patient population that we believe has the highest unmet need,” said Mr. Michael Amoroso, CEO of Precision BioSciences.

References:

[1] Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population. Retrieved June 8, 2022, from https://www.businesswire.com/news/home/20220608005433/en/

New cell therapy brings new hope for relapsed patients treated by CAR-T treatment.

(source:internet, reference only)

Disclaimer of medicaltrend.org

Important Note: The information provided is for informational purposes only and should not be considered as medical advice.